title: Uptake of screening and prevention in women at very high risk of breast cancer.
abstract: Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.
authors.forename: D
authors.initials: D
authors.lastname: Evans
authors.forename: F
authors.initials: F
authors.lastname: Lalloo
authors.forename: A
authors.initials: A
authors.lastname: Shenton
authors.forename: C
authors.initials: C
authors.lastname: Boggis
authors.forename: A
authors.initials: A
authors.lastname: Howell
mesh_terms: D000328:Adult; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control* / Q000601:surgery; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics; D006801:Humans; D008279:Magnetic Resonance Imaging; D008403:Mass Screening / Q000379:methods; D008408:Mastectomy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics; D012307:Risk Factors; D014157:Transcription Factors / Q000235:genetics
chemical_list: D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors